LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

Search

Guardant Health Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

84.75 -0.42

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

84.55

Max

87.97

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-36M

-128M

Pardavimai

16M

281M

Pelnas, tenkantis vienai akcijai

-0.5

Pelno marža

-45.684

Darbuotojai

2,490

EBITDA

-37M

-119M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+55.81% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-2.2B

11B

Ankstesnė atidarymo kaina

85.17

Ankstesnė uždarymo kaina

84.75

Naujienos nuotaikos

By Acuity

50%

50%

147 / 350 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-22 23:50; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-03-22 23:50; UTC

Rinkos pokalbiai

LG Electronics Set to Stage Strong Earnings Rebound in 1Q -- Market Talk

2026-03-22 23:49; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Edges Lower on Prospects of Liquidity-Driven Sales -- Market Talk

2026-03-22 23:49; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Nikkei May Fall as Concerns About Middle East Conflict Persist -- Market Talk

2026-03-22 23:49; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Global Forex and Fixed Income Roundup: Market Talk

2026-03-22 23:41; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Oil Edges Lower as Traders Eye Trump's Deadline to Reopen Strait of Hormuz -- Market Talk

2026-03-22 22:57; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Location of Aurum's Discoveries Present Potential Future Synergies

2026-03-22 22:56; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Aurum Share Acquisition Cost A$23.69 Million

2026-03-22 22:56; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Aurum's Boundiali Gold Project Located to South of Sissingue Gold Mine

2026-03-22 22:55; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Participated in Aurum Resources Equity Raising

2026-03-22 22:54; UTC

Įsigijimai, susijungimai, perėmimai

Perseus Mining: Acquires 9.9% Interest in Aurum Resources

2026-03-22 22:22; UTC

Rinkos pokalbiai
Svarbiausios naujienos

After Selloff, Gold Seen Supported by Strait of Hormuz Deadline -- Market Talk

2026-03-22 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Synopsys Has Market Value Over $80 Billion; Major Customers Include Nvidia -- WSJ

2026-03-22 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Activist Elliott Builds Big Stake in Chip-Design Software Maker Synopsys -- WSJ

2026-03-22 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Activist Elliott Investment Management Has Multibillion-Dollar Investment in Synopsys, Sources Say -- WSJ

2026-03-22 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Elliott Plans to Push Synopsys to Make More Money From Its Software and Services, Sources Say -- WSJ

2026-03-22 21:53; UTC

Uždarbis

Zijin Gold International Plans 59.2 Tons of Gold Production in 2026; up 12.3% on Year >2259.HK

2026-03-22 21:53; UTC

Uždarbis

Zijin Gold International Rising Gold Prices Supported Results >2259.HK

2026-03-22 21:53; UTC

Uždarbis

Zijin Gold International 2025 Rev $5.38B Vs. $2.99B >2259.HK

2026-03-22 21:53; UTC

Uždarbis

Zijin Gold International 2025 Net $1.60B Vs. Net $481.37M >2259.HK

2026-03-22 21:31; UTC

Uždarbis

China Petroleum & Chemical Plans CNY131.6B-CNY148.6B Capex Spending in 2026>0386.HK

2026-03-22 21:31; UTC

Uždarbis

China Petroleum & Chemical: Decrease in Sales Volumes of Refined Oil Products Also Hurt Results >0386.HK

2026-03-22 21:31; UTC

Uždarbis

China Petroleum & Chemical 2025 Results Weighed by Decrease in Prices of Petroleum, Petrochemical Products>0386.HK

2026-03-22 21:31; UTC

Uždarbis

China Petroleum & Chemical 2025 Rev CNY2.78T Vs. CNY3.07T >0386.HK

2026-03-22 21:31; UTC

Uždarbis

China Petroleum & Chemical 2025 Net CNY32.48B Vs. Net CNY48.94B >0386.HK

2026-03-22 21:25; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Bonds Decoupling From Oil Amid Longer Conflict Fears -- Market Talk

2026-03-22 21:22; UTC

Įsigijimai, susijungimai, perėmimai

St Barbara: Remarks Follow Recent Inquiries About Simberi's Fuel Stocks

2026-03-22 21:21; UTC

Įsigijimai, susijungimai, perėmimai

St Barbara: Simberi Currently Uses About 65,000 Liters Per Day For Mining Fleet, Power Generation

2026-03-22 21:21; UTC

Rinkos pokalbiai

Revised Fuel Subsidy Mechanism Positive for Ampol, Viva Energy -- Market Talk

2026-03-22 21:21; UTC

Įsigijimai, susijungimai, perėmimai

St Barbara: Has Been Taking Precaution to Increase Diesel Storage For Several Months

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

55.81% į viršų

12 mėnesių prognozė

Vidutinis 132.72 USD  55.81%

Aukščiausias 175 USD

Žemiausias 110 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

20 ratings

19

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

147 / 350 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat